poisar

Stocks · News reference

Grifols Announces Completion Of Follow-Up For All 345 Patients In Phase 3 SPARTA Trial Of Prolastin-C In Alpha-1 Emphysema; Topline Data Expected By End Of 2026

BenzingaAug 10, 2026, 11:06 AMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 10, 2026, 11:06 AM
Checked
Aug 10, 2026, 11:06 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncJul 22, 2026, 6:00 PMHealthcare Foresights

    [Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

    The global botulinum toxin in urology market is projected to grow from USD 1.1 billion in 2025 to USD 1.98 billion by 2035, at a CAGR of 6.08%. Growth is driven by increasing prevalence of urological disorders, aging populations, preference for minimally invasive treatments, and advancements in injection techniques. OnabotulinumtoxinA (Botox) leads the market, with overactive bladder being the largest application segment.

    Read original at globenewswire-inc